family with sequence similarity 149 member B1Genealiases: JBTS36 · KIAA0974
Q-omics provides the consensus-scored FAM149B1 profile across patient tissues and cancer cell-line models. FAM149B1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, FAM149B1 is differentially expressed in 7, with the highest sampling consensus in LIHC. Additionally, FAM149B1 RNA expression shows 21,113 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and LIHC as cancer lineages where FAM149B1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM149B1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM149B1 survival associations across molecular data types. FAM149B1 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM149B1 RNA expression–survival associations across cancer types. High FAM149B1 expression shows unfavorable associations in ACC, UVM and BLCA, but favorable associations in KIRC, LGG and LUAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for FAM149B1 RNA expression.
This table summarizes FAM149B1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for FAM149B1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM149B1 shows lower tumor expression in KICH and THCA and higher tumor expression in LIHC, CHOL, LUAD and STAD. The LIHC box plot shows higher FAM149B1 RNA expression in tumor versus normal tissue (log2 FC = +0.754, t-test p < 0.001).
This table shows molecular features associated with FAM149B1 in patient tissues and cancer cell lines. In patient samples, FAM149B1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM149B1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
